These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 26786511)

  • 1. The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1.
    Strauss RW; Ho A; Muñoz B; Cideciyan AV; Sahel JA; Sunness JS; Birch DG; Bernstein PS; Michaelides M; Traboulsi EI; Zrenner E; Sadda S; Ervin AM; West S; Scholl HP;
    Ophthalmology; 2016 Apr; 123(4):817-28. PubMed ID: 26786511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7.
    Schönbach EM; Wolfson Y; Strauss RW; Ibrahim MA; Kong X; Muñoz B; Birch DG; Cideciyan AV; Hahn GA; Nittala M; Sunness JS; Sadda SR; West SK; Scholl HPN;
    JAMA Ophthalmol; 2017 Jul; 135(7):696-703. PubMed ID: 28542693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Atrophic Lesions in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 5.
    Strauss RW; Muñoz B; Ho A; Jha A; Michaelides M; Mohand-Said S; Cideciyan AV; Birch D; Hariri AH; Nittala MG; Sadda S; Scholl HPN;
    JAMA Ophthalmol; 2017 Jul; 135(7):687-695. PubMed ID: 28542697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9).
    Strauss RW; Muñoz B; Ho A; Jha A; Michaelides M; Cideciyan AV; Audo I; Birch DG; Hariri AH; Nittala MG; Sadda S; West S; Scholl HPN;
    JAMA Ophthalmol; 2017 Nov; 135(11):1232-1241. PubMed ID: 29049437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Progression of the Stargardt Disease Type 4 (ProgStar-4) Study: Design and Baseline Characteristics (ProgStar-4 Report No. 1).
    Strauss RW; Muñoz B; Ahmed MI; Bittencourt M; Schönbach EM; Michaelides M; Birch D; Zrenner E; Ervin AM; Charbel Issa P; Kong J; Wolfson Y; Shah M; Bagheri S; West S; Scholl HPN;
    Ophthalmic Res; 2018; 60(3):185-194. PubMed ID: 30110705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Microperimetric Changes of Macular Sensitivity in Stargardt Disease After 12 Months: ProgStar Report No. 13.
    Schönbach EM; Strauss RW; Muñoz B; Wolfson Y; Ibrahim MA; Birch DG; Zrenner E; Sunness JS; Ip MS; Sadda SR; West SK; Scholl HPN;
    JAMA Ophthalmol; 2020 Jul; 138(7):772-779. PubMed ID: 32463436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual Acuity Change over 12 Months in the Prospective Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: ProgStar Report Number 6.
    Kong X; Strauss RW; Cideciyan AV; Michaelides M; Sahel JA; Munoz B; Ahmed M; Ervin AM; West SK; Cheetham JK; Scholl HPN;
    Ophthalmology; 2017 Nov; 124(11):1640-1651. PubMed ID: 28549516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption in Bruch membrane in patients with Stargardt disease.
    Park SP; Chang S; Allikmets R; Smith RT; Burke TR; Gregory-Roberts E; Tsang SH
    Ophthalmic Genet; 2012 Mar; 33(1):49-52. PubMed ID: 22060670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric Inter-Eye Progression in Stargardt Disease.
    Lambertus S; Bax NM; Groenewoud JM; Cremers FP; van der Wilt GJ; Klevering BJ; Theelen T; Hoyng CB
    Invest Ophthalmol Vis Sci; 2016 Dec; 57(15):6824-6830. PubMed ID: 28002570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early-onset stargardt disease: phenotypic and genotypic characteristics.
    Lambertus S; van Huet RA; Bax NM; Hoefsloot LH; Cremers FP; Boon CJ; Klevering BJ; Hoyng CB
    Ophthalmology; 2015 Feb; 122(2):335-44. PubMed ID: 25444351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. En Face Spectral-Domain Optical Coherence Tomography for the Monitoring of Lesion Area Progression in Stargardt Disease.
    Melillo P; Testa F; Rossi S; Di Iorio V; Orrico A; Auricchio A; Simonelli F
    Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT247-52. PubMed ID: 27409479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal analysis of the Preferred Retinal Location and the Transition Zone in patients with Stargardt Disease.
    Verdina T; Greenstein VC; Sodi A; Tsang SH; Burke TR; Passerini I; Allikmets R; Virgili G; Cavallini GM; Rizzo S
    Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1307-1317. PubMed ID: 28365912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and genetic characteristics of late-onset Stargardt's disease.
    Westeneng-van Haaften SC; Boon CJ; Cremers FP; Hoefsloot LH; den Hollander AI; Hoyng CB
    Ophthalmology; 2012 Jun; 119(6):1199-210. PubMed ID: 22449572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visual Acuity Change Over 24 Months and Its Association With Foveal Phenotype and Genotype in Individuals With Stargardt Disease: ProgStar Study Report No. 10.
    Kong X; Fujinami K; Strauss RW; Munoz B; West SK; Cideciyan AV; Michaelides M; Ahmed M; Ervin AM; Schönbach E; Cheetham JK; Scholl HPN;
    JAMA Ophthalmol; 2018 Aug; 136(8):920-928. PubMed ID: 29902293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal imaging and multifocal electroretinography demonstrate autosomal recessive Stargardt disease may present like occult macular dystrophy.
    Sisk RA; Leng T
    Retina; 2014 Aug; 34(8):1567-75. PubMed ID: 24743636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Progression of Stargardt Disease as Determined by Spectral-Domain Optical Coherence Tomography over a 24-Month Period (ProgStar Report No. 18).
    Strauss RW; Lang L; Ho A; Jha A; Ip M; Bernstein PS; Birch DG; Cideciyan AV; Michaelides M; Audo I; Sunness JS; Traboulsi EI; Zrenner E; Sadda SR; Janeschitz-Kriegl L; West S; Kong X; Scholl HPN;
    Ophthalmic Res; 2024; 67(1):435-447. PubMed ID: 39004077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostication in Stargardt Disease Using Fundus Autofluorescence: Improving Patient Care.
    Daich Varela M; Laich Y; Hashem SA; Mahroo OA; Webster AR; Michaelides M
    Ophthalmology; 2023 Nov; 130(11):1182-1190. PubMed ID: 37331482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of Geographic Atrophy Using Spectral Domain OCT in Age-Related Macular Degeneration.
    Cleland SC; Konda SM; Danis RP; Huang Y; Myers DJ; Blodi BA; Domalpally A
    Ophthalmol Retina; 2021 Jan; 5(1):41-48. PubMed ID: 32679202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morpho-functional correlation of fundus autofluorescence in Stargardt disease.
    Parodi MB; Iacono P; Triolo G; La Spina C; Zucchiatti I; Cicinelli MV; Borrelli E; Manitto MP; Martina E; Bandello F
    Br J Ophthalmol; 2015 Oct; 99(10):1354-9. PubMed ID: 25837607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural History of Geographic Atrophy Progression Secondary to Age-Related Macular Degeneration (Geographic Atrophy Progression Study).
    Schmitz-Valckenberg S; Sahel JA; Danis R; Fleckenstein M; Jaffe GJ; Wolf S; Pruente C; Holz FG
    Ophthalmology; 2016 Feb; 123(2):361-368. PubMed ID: 26545317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.